Medicare Part B

Controversy heats up over pharmacy benefit manager DIR feesPBMs make the argument for DIR fees after a litany of complaints from industry stakeholders.
NACDS’ New CourseExpanded scope-of-practice/health-and-wellness figure prominently in new strategy.
Business Group Makes Price Recommendations for Specialty Drugs
Business Group Makes Price Recommendations for Specialty DrugsThe high cost of specialty drugs demands a change in Washington, according to a report.
What health execs should know about Medicare Star Ratings
What health execs should know about Medicare Star RatingsThe Medicare Star Ratings program is one way regulators are trying to improve outcomes while reducing costs, but what is really at stake for health plans, and do consumers even care?
Medicare Part B drug pay proposal could undergo revision
Medicare Part B drug pay proposal could undergo revisionFollowing a flood of criticism from the pharmaceutical lobby, medical societies, patient groups and members of Congress, the Centers for Medicare & Medicaid Services (CMS) has announced it may make some adjustments to its Medicare Part B drug pay proposal.
Eleven ways MACRA will impact your businessWhat impact will MACRA have on your organization? We asked experts to tell us.
CMS’ Medicare Part B drug proposal: 5 things to knowThe goal of CMS’ proposal is to reduce costs while rewarding better outcomes for patients. Here are five things healthcare executives need to know.
Provider statusWith provider status now a reality in 38 states, HR 592 and S 314 have powerful Congressional support. How long before the payers come on board?
Impact of Medicare's expanded benzodiazepine coverageLike any medication, benzodiazepines should be used with caution. However, the tremendous expenditure for these medications—just a year after Medicare Part D extended its coverage to include them in 2012—has some wondering why so many of these drugs are being prescribed.
Proposed Medicare Part B rule would cut payments for some drugsNew analysis finds proposed Medicare payment changes for physician-administered drugs would reduce reimbursement for those that cost more than $480 per day in 2016. Seven of the 10 drugs that constitute the largest reduction in reimbursement are used to treat cancer.